Compare BIO-TECHNE Corp (TECH) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Walmart Stores Inc — how do they compare? BIO-TECHNE Corp trades at $71.79 (market cap $11.16B), while Walmart Stores Inc trades at $110.49 (market cap $892.90B). The key difference: Walmart Stores Inc is far larger — about 80× BIO-TECHNE Corp's market cap, and Walmart Stores Inc pays the higher dividend (0.88%). Which is the better fit depends on your goals.
| TECH | WMT | |
|---|---|---|
Market Cap | $11.16B | $892.90B |
Sector | Health | Consumer Staples |
52-Week High | $72.12 | $134.20 |
52-Week Low | $43.31 | $95.67 |
Enterprise Value | $11.24B | $956.35B |
Dividend Yield | 0.45% | 0.88% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Walmart (WMT) trades at $114.24, down 0.62% today, with a neutral technical signal and strong fundamentals including consistent earnings beats and robust cash flow. Revenue reached $681.0B in 2025 (source: company filings, 2025), with net income margin improving to 3.13%. Recent news highlights AI innovation and delivery expansion, while analyst consensus remains bullish with a $142.10 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include competitive pressure from Amazon and margin volatility. Wall Street's strong buy rating (72.72% of analysts) supports upside potential, though investors should monitor execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
